Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study
Purpose: To search for new predictive breast cancer biomarkers. We analyzed the serum concentrations of biomarkers involved in carcinogenesis, which can also be targeted by therapy. Methods: In a single-center prospective study, the serum levels of Aurora A, thymidine kinase 1, and human epidermal g...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/22/5446 |
| _version_ | 1797459852791906304 |
|---|---|
| author | Pawel Winter Malgorzata Fuksiewicz Agnieszka Jagiello-Gruszfeld Zbigniew Nowecki Beata Kotowicz |
| author_facet | Pawel Winter Malgorzata Fuksiewicz Agnieszka Jagiello-Gruszfeld Zbigniew Nowecki Beata Kotowicz |
| author_sort | Pawel Winter |
| collection | DOAJ |
| description | Purpose: To search for new predictive breast cancer biomarkers. We analyzed the serum concentrations of biomarkers involved in carcinogenesis, which can also be targeted by therapy. Methods: In a single-center prospective study, the serum levels of Aurora A, thymidine kinase 1, and human epidermal growth factor receptor type 3 (HER3) were determined in 119 women with BC before neoadjuvant treatment using ELISA kits. Results: The following clinical data were analyzed: age; TNM; the expression of ER, PGR, HER2, and Ki67; histological grade (G); and the response to neoadjuvant treatment (NAT) in the residual tumor burden classification (RCB). A complete pathological response (pCR) was achieved after NAT in 41 patients (34%). The highest proportion of the patients with a confirmed pCR was found for triple negative breast cancer (TNBC) (62.5%); non-luminal HER2-positive (52.6%) cancer subtypes (<i>p</i> = 0.0003); and in the G3 group (50%; <i>p</i> = 0.0078). The patients with higher levels of Aurora A were more likely to achieve pCR (<i>p</i> = 0.039). In the multivariate analysis, the serum Aurora A levels ≥ 4.75 ng/mL correlated with a higher rate of pCR (OR: 3.5; 95% CI: 1.2–10.1; <i>p</i> = 0.023). Conclusions: We showed that in a biologically heterogeneous group of BC patients, the pretreatment serum Aurora A levels were of significant value in predicting the response to NAT. |
| first_indexed | 2024-03-09T16:56:51Z |
| format | Article |
| id | doaj.art-913e1831790f413180a413838d22ac29 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T16:56:51Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-913e1831790f413180a413838d22ac292023-11-24T14:34:32ZengMDPI AGCancers2072-66942023-11-011522544610.3390/cancers15225446Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot StudyPawel Winter0Malgorzata Fuksiewicz1Agnieszka Jagiello-Gruszfeld2Zbigniew Nowecki3Beata Kotowicz4Breast Cancer and Reconstructive Surgery Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandCancer Biomarker and Cytokines Laboratory Unit, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandBreast Cancer and Reconstructive Surgery Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandBreast Cancer and Reconstructive Surgery Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandCancer Biomarker and Cytokines Laboratory Unit, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandPurpose: To search for new predictive breast cancer biomarkers. We analyzed the serum concentrations of biomarkers involved in carcinogenesis, which can also be targeted by therapy. Methods: In a single-center prospective study, the serum levels of Aurora A, thymidine kinase 1, and human epidermal growth factor receptor type 3 (HER3) were determined in 119 women with BC before neoadjuvant treatment using ELISA kits. Results: The following clinical data were analyzed: age; TNM; the expression of ER, PGR, HER2, and Ki67; histological grade (G); and the response to neoadjuvant treatment (NAT) in the residual tumor burden classification (RCB). A complete pathological response (pCR) was achieved after NAT in 41 patients (34%). The highest proportion of the patients with a confirmed pCR was found for triple negative breast cancer (TNBC) (62.5%); non-luminal HER2-positive (52.6%) cancer subtypes (<i>p</i> = 0.0003); and in the G3 group (50%; <i>p</i> = 0.0078). The patients with higher levels of Aurora A were more likely to achieve pCR (<i>p</i> = 0.039). In the multivariate analysis, the serum Aurora A levels ≥ 4.75 ng/mL correlated with a higher rate of pCR (OR: 3.5; 95% CI: 1.2–10.1; <i>p</i> = 0.023). Conclusions: We showed that in a biologically heterogeneous group of BC patients, the pretreatment serum Aurora A levels were of significant value in predicting the response to NAT.https://www.mdpi.com/2072-6694/15/22/5446breast cancerneoadjuvant treatmentpredictive markerAURKAAurora AHER3 |
| spellingShingle | Pawel Winter Malgorzata Fuksiewicz Agnieszka Jagiello-Gruszfeld Zbigniew Nowecki Beata Kotowicz Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study Cancers breast cancer neoadjuvant treatment predictive marker AURKA Aurora A HER3 |
| title | Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study |
| title_full | Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study |
| title_fullStr | Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study |
| title_full_unstemmed | Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study |
| title_short | Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study |
| title_sort | expression of soluble form of aurora a as a predictive factor for neoadjuvant therapy in breast cancer patients a single center pilot study |
| topic | breast cancer neoadjuvant treatment predictive marker AURKA Aurora A HER3 |
| url | https://www.mdpi.com/2072-6694/15/22/5446 |
| work_keys_str_mv | AT pawelwinter expressionofsolubleformofauroraaasapredictivefactorforneoadjuvanttherapyinbreastcancerpatientsasinglecenterpilotstudy AT malgorzatafuksiewicz expressionofsolubleformofauroraaasapredictivefactorforneoadjuvanttherapyinbreastcancerpatientsasinglecenterpilotstudy AT agnieszkajagiellogruszfeld expressionofsolubleformofauroraaasapredictivefactorforneoadjuvanttherapyinbreastcancerpatientsasinglecenterpilotstudy AT zbigniewnowecki expressionofsolubleformofauroraaasapredictivefactorforneoadjuvanttherapyinbreastcancerpatientsasinglecenterpilotstudy AT beatakotowicz expressionofsolubleformofauroraaasapredictivefactorforneoadjuvanttherapyinbreastcancerpatientsasinglecenterpilotstudy |